



# Department of Medicaid

John R. Kasich, Governor  
John B. McCarthy, Director

## Pharmacy & Therapeutics Committee Meeting

Wednesday, April 9, 2013

Rhodes State Office Tower, Room 2925

30 E. Broad St.

10:00 AM

- A. Conflict of Interest Policy
- B. Interested Party Presentations
- C. Old Business

Preferred Drug List (PDL) proposed changes to be discussed at June P&T meeting

### D. New Business: Drugs Under Review

- 1. Infectious Disease Agents, Hepatitis C
  - a) Sovaldi™ (sofosbuvir tablets), Gilead Sciences, Inc.
  - b) Olysio™ (simepravir capsule), Janssen Therapeutics
- 2. Genitourinary Agents, Electrolyte Depletor Agents: Velphoro® (sucroferric oxyhydroxide chewable tablets), Fresenius Medical Care
- 3. Endocrine Agents, Diabetes Oral Hypoglycemics: Farxiga™ (dapagliflozin tablets), Astra Zeneca Pharmaceuticals
- 4. CNS Agents, Antidepressants: Fetzima™ (levomilnacipran ER capsules), Forest Pharmaceuticals
- 5. CNS Agents, Anticonvulsants: Fycompa™ (perampanel tablets CIII), Eisai Inc.

Remaining 2014 meetings:

June 11, 9 AM, Riffe Building 31<sup>st</sup> Floor

October 8, 10 AM, location to be determined



# Department of Medicaid

John R. Kasich, Governor  
John B. McCarthy, Director

## Pharmacy and Therapeutics Committee Conflict of Interest Policy

Purpose: To require members of the Department of Medicaid Pharmacy and Therapeutics Committee to abide by this policy so that scientific and economic data serves as the primary basis in rendering objective decisions about drugs being considered for coverage by Ohio Medicaid.

Definition: A potential “conflict of interest” may exist when a committee member has a relationship with a manufacturer of the medication or class of medications being considered that could inappropriately influence his/her judgment, or the judgment of other members. This may include a relationship with a manufacturer of a drug which competes with the drug under consideration. A relationship with a manufacturer may include any of the following:

- Acceptance of honoraria
- Participation in speaker’s bureau
- Acceptance of support for travel for professional or education activities
- Acceptance of research support
- Relationship valued at \$500 or more with one company
- Consultant arrangement

### Policy Statements

1. A member shall not participate in the discussion of an issue that is before the committee unless he/she has first disclosed any potentially relevant conflict of interest.
2. The committee will determine if a specific activity or relationship represents a potential conflict of interest and whether the member disclosing a potentially relevant conflict should continue to participate in the discussion.

Procedure: Committee members must sign this agreement once each year.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name \_\_\_\_\_